Slowing Gastric Emptying: By delaying the movement of food from the stomach to the small intestine, GLP-1 helps to flatten post-meal glucose spikes and promotes a feeling of fullness
Reported side effects include: Other side effects reported include reduced appetite (also a side effect of the drug), tiredness, and skin sensitivity
Advanced / Aggressive Protocol (1 mL = ~10.0 mg/mL) Note: The 12 mg dose represents the highest dose tested in Phase 2 trials [3] [4] , producing maximum weight-loss efficacy (~24% body weight at 48 weeks)
Kommu, S., & Whitfield, P
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of medications originally developed for managing type 2 diabetes, with some now also approved for weight management
Untested formulations Semaglutide and tirzepatide are FDA-approved as injectables (an oral tablet version of semaglutide is also approved), but the formulations some drug compounding pharmacies are selling in the form of sublingual drops or dissolving tablets have never been studied in clinical trials
